This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The company is already marketing the 4 mg and 10 mg strengths
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
Convergent action on AMR identified as an important area of intervention
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
UTD2 is the world's first oral epothilone microtubule inhibitor
Subscribe To Our Newsletter & Stay Updated
